Results 271 to 280 of about 197,147 (332)

GLP-1 and GIP Beyond Glycaemia: Evolutionary Roles in Energy Optimisation and Organ Protection. [PDF]

Diabetes Metab Res Rev
Tuccinardi D, Watanabe M, Masi D, Gianfrilli D, Manfrini S, le Roux CW.   +5 more
europepmc   +1 more source

Transcriptional regulation of neuropeptide receptors underlies context-dependent adaptation in Drosophila melanogaster. [PDF]

FEBS Open Bio
Ryu S, Wei Y, Wu Z, Zhang T, Lee D, Najafi H, Kim WJ.   +6 more
europepmc   +1 more source

Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation. [PDF]

Cardiovasc Res
Jani NR, van Weperen VYH, Ayagama T, Hoang JD, Emamimeybodi M, Bussmann BM, Bal S, Kumar A, Khaky A, Hamon D, Herring N, Smith C, Vaseghi M.   +12 more
europepmc   +1 more source

Heartfelt intervention: A role for PVN oxytocin neurons in the prediabetic heart

The Journal of Physiology, EarlyView.
Grace K. Nielsen, Reesa M. Wilcox, Han‐Jun Wang   +2 more
wiley   +1 more source

A gene expression atlas of a juvenile nervous system

Taylor SR, Olson C, Ripoll-Sanchez L, Valperga G, McWhirter R, Barney ST, Atkinson A, Goel S, Weinreb A, Hardin A, Rolfson A, Pattee J, Aguilar GR, Merritt DM, Eroglu M, Majeed M, Grundvig E, Child E, Beets I, Vértes PE, Schafer WR, Varol E, Hammarlund M, Hobert O, Miller DM.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neuropeptide Y receptor subtypes

Life Sciences, 1995
Neuropeptide Y (NPY) is an amidated 36-amino acid peptide with a wide distribution in the central and peripheral nervous system. It can evoke numerous physiological responses by activating specific receptors. Studies using NPY analogs in various model systems and cell types demonstrate different orders of ligand potency and receptor binding affinity ...
C P, Wan, B H, Lau
openaire   +2 more sources

Dihydropyridine Neuropeptide Y Y1 Receptor Antagonists

Bioorganic & Medicinal Chemistry Letters, 2002
Dihydropyridine 5a was found to be an inhibitor of neuropeptide Y(1) binding in a high throughput (125)I-PYY screening assay. Structure-activity studies around certain portions of the dihydropyridine chemotype identified BMS-193885 (6e) as a potent and selective Y(1) receptor antagonist.
Graham S, Poindexter, Marc A, Bruce, Karen L, LeBoulluec, Ivo, Monkovic, Scott W, Martin, Eric M, Parker, Larry G, Iben, Rachel T, McGovern, Astrid A, Ortiz, Jennifer A, Stanley, Gail K, Mattson, Michael, Kozlowski, Meredith, Arcuri, Ildiko, Antal-Zimanyi   +13 more
openaire   +2 more sources